*Running title: Schizophrenia, severe hepatic outcome, and paliperidone*

*Financial Disclosure: The authors have indicated they have no relevant financial relationships to disclose for this article.*

*Conflicts of Interest: The authors declare that there is no conflict of interest.*

*Contributor's Statement:*

*Chun-Hung Chang conceptualized and designed the study, database processing and drafted the initial manuscript.*

*Shaw-Ji Chen, and Chieh-Yu Liu provided expert opinions and reviewed the final submitted manuscript.*

*Hsien-Yuan Lane is in charge of this study, including applying the research database, conducting the data analysis and critically reviewed the manuscript, and approved the final submitted manuscript*

**Abstract**

**Objective**: Paliperidone exhibits protective effects for liver, but the association between paliperidone use and the risk of severe hepatic outcome in schizophrenia patients with viral hepatitis is unknown. This population-based study is aimed to assess the incidence and risk of severe hepatic outcome among schizophrenia patients with viral hepatitis who received paliperidone.

**Methods:** Using a nationwide database, the Taiwan National Health Insurance Research Database, subjects who had first been diagnosed with schizophrenia between 2007 and 2013 were identified. The schizophrenia patients with viral hepatitis receiving paliperidone were designated as the paliperidone group. A 1:2 ratio was used to select age-, gender-, and index-year -matched control without paliperidone use. Patients who had severe hepatic outcome before enrollment were excluded. The 2 cohorts were observed until December 31, 2013. The primary endpoint was occurrence of severe hepatic outcome including liver failure, liver decompensation, liver transplantation, and liver cancer.

**Results:** Among 953 newly diagnosed schizophrenia patients with viral hepatitis, we identified 134 patients with paliperidone use, and 268 matched patients without paliperidone use between January 2007 and December 2013. Of the 402 patients, 22 (5.47%) suffered from severe hepatic outcome during a mean follow-up period of 6.639 years, including 2 (1.49%) from the paliperidone cohort and 20 (7.46%) from the control group. In schizophrenia patients with viral hepatitis, the Cox multivariate proportional hazards analysis showed that the risk decreased with paliperidone use 0.1938 (95% confidence interval (CI), 0.0802 to 0.4681; p = 0.0135).

**Conclusions:** Paliperidone use was associated with a reduced risk of severe hepatic outcome among schizophrenia patients with viral hepatitis.
